C19orf56 Inhibitors
C19orf56 inhibitors are a class of chemical compounds that target various signaling pathways and enzymes to indirectly diminish the activity of C19orf56. For example, kinase inhibitors like staurosporine exert their effect by broadly inhibiting protein kinases, which are essential for phosphorylating proteins that may be necessary for the proper functioning of C19orf56. Inhibition of these kinases would prevent the phosphorylation and subsequent activation of proteins involved in the regulation of C19orf56 activity, thereby leading to its reducedfunctional activity.
Compounds such as LY294002 and wortmannin specifically inhibit the PI3K/AKT signaling pathway. This pathway is critical for numerous cellular functions, including survival, growth, and metabolism. Since it is plausible that C19orf56 functions downstream of or is regulated by PI3K/AKT signaling, the inhibition of this pathway by LY294002 and wortmannin would result in an indirect reduction of C19orf56 activity by preventing essential phosphorylation events or the activation of secondary messengers that modulate its activity. Similarly, the inhibition of mTOR by rapamycin could lead to decreased C19orf56 activity if C19orf56 is involved in pathways downstream of mTOR, such as protein synthesis or cell cycle progression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is an alkaloid that acts as a potent, non-selective inhibitor of protein kinases. By inhibiting a broad range of kinases, it can suppress the phosphorylation of target proteins, potentially including those that might be necessary for C19orf56 activity. Thus, staurosporine can indirectly inhibit C19orf56 by preventing the activation of kinases required for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a synthetic molecule that specifically inhibits PI3K. By blocking PI3K, LY294002 can prevent the activation of the AKT signaling pathway. Since C19orf56 may be regulated by PI3K/AKT signaling, inhibition of this pathway by LY294002 could lead to reduced C19orf56 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroid metabolite that acts as a potent and irreversible inhibitor of PI3K. Its action on the PI3K pathway blocks downstream AKT activation. As C19orf56 could be indirectly regulated by PI3K/AKT signaling, the inhibition by wortmannin would result in decreased C19orf56 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a macrolide compound that inhibits mTOR, a key regulatory kinase. By inhibiting mTOR, rapamycin can disrupt downstream signaling pathways that are crucial for cell growth and proliferation. This disruption may indirectly inhibit C19orf56 if it is involved in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes that are part of the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can prevent the phosphorylation and activation of ERK, which might be necessary for the functional activity of C19orf56. Therefore, U0126 can indirectly inhibit C19orf56 by blocking its downstream signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a synthetic compound that selectively inhibits MEK, which is upstream in the MAPK/ERK pathway. The inhibition of MEK prevents the activation of downstream ERK, potentially leading to reduced activity of proteins regulated by this pathway, including possibly C19orf56. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several kinases including Raf, which is a part of the Raf/MEK/ERK signaling cascade. By inhibiting Raf, Sorafenib can decrease the signaling through the MEK/ERK pathway and thus indirectly lower C19orf56 activity if it is regulated by this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins. By stabilizing proteins that may negatively regulate C19orf56, bortezomib can indirectly lead to its decreased activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. By inhibiting Src kinases, it can disrupt multiple signaling pathways, including those that might regulate or interact with C19orf56, potentially leading to an indirect inhibition of C19orf56. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $113.00 $1035.00 | 7 | |
AZD0530 is a selective inhibitor of Src family kinases. By blocking the activity of these kinases, AZD0530 may interfere with signaling pathways that control the function of C19orf56, thus leading to its indirect inhibition. | ||||||